Drug-Coated Stents Inhibit Restenosis in Pigs

After 28 days, the drug-coated stents showed a dramatic improvement in reduction in neointima as well as improvement in artery size, compared to the uncoated stents. The proprietary drug used in the study was developed by Abbott Laboratories (Abbott Park, Il, USA). The company is now conducting more studies, preparatory to moving into human clinical trials.

"Vascular medicine still has unmet needs as in indicated by the rate of restenosis in many coronary artery disease patients,” said Patrick J. Balthrop, vice president, vascular devices, Abbott Laboratories. "Emerging technologies, like drug-coated stents, may help patients avoid additional angioplasty or bypass surgery.”



Related Links:
Abbott Laboratories